Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
37,883,682

-0.22 (-0.77%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Nalak Das headshot

Top 6 Momentum Picks for November After a Fabulous October

We have narrowed down our search to six large-cap momentum stocks that have strong upside left for the rest of 2021. These are: BX, Ce, CLR, XLNX, BG, GPC.

4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Kinjel Shah headshot

Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab

Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.

Why Pfizer (PFE) Might Surprise This Earnings Season

Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Glaxo (GSK) Beats on Q3 Earnings, Gives Improved EPS View

Glaxo's (GSK) revenues benefit from the recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

Sweta Killa headshot

Healthcare ETFs in Focus as Q3 Earnings Unfold

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Will Pfizer (PFE) Keep the Earnings Streak Alive in Q3?

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View

Bristol-Myers (BMY) beats on earnings and sales in the third quarter on the back of Revlimid, Eliquis, and Opdivo.

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $43.56, moving +0.95% from the previous trading session.

Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.

Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales

Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.

Sweta Jaiswal, FRM headshot

Will Pfizer ETFs Gain on Positive COVID-19 Booster Dose Data?

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in the coronavirus vaccine.

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.

Glaxo (GSK) to Report Q3 Earnings: What's in the Cards?

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine prioritization may have continued.

Mark Vickery headshot

Big Week for FAANG, Economic Reads

The Dow is +25 points, the S&P 500 +5 and the tech-heavy Nasdaq, which houses the FAANG stocks, is +45 points at this hour.

Tech Giants to Report Earnings This Week

Tech Giants to Report Earnings This Week

How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Q3 Earnings Season Moving Along

Q3 Earnings Season Moving Along

Mark Vickery headshot

Reasons for Optimism: Q3 Earnings, Infrastructure

Not only good Q3 numbers, but Covid vaccine news and hope for an infrastructure passage are keeping bullish sentiment in the market.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters

J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.

Pfizer's (PFE) Comirnaty Booster Dose Achieves 95.6% Efficacy

Pfizer (PFE) and BioNTech announce promising data from a late-stage study evaluating the booster dose of their COVID-19 vaccine, Comirnaty.

Fastly, PagerDuty, Johnson & Johnson, Moderna and Pfizer highlighted as Zacks Bull and Bear of the Day

Fastly, PagerDuty, Johnson & Johnson, Moderna and Pfizer highlighted as Zacks Bull and Bear of the Day